T. Rowe Price Associates
BIOA

T. Rowe Price Associates’s BioAge Labs BIOA Stock Holding History

T. Rowe Price Associates’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$375K Buy
21,418
+6,610
+45% +$127K ﹤0.01% 2568
2025
Q4 		$196K Buy
14,808
+2,917
+25% +$25.9K ﹤0.01% 2817
2025
Q3 		$70K Buy
+11,891
New +$55.7K ﹤0.01% 2978
2024
Q4 		– Sell
-449,837
Closed -$9.36M – 3066
2024
Q3 		$9.36M Buy
+449,837
New +$9.01M ﹤0.01% 1148

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates's BIOA Position: Q1 2026 in Review

T. Rowe Price Associates increased its BioAge Labs (BIOA) stake by 45% in Q1 2026, buying an estimated $127K and bringing the position to 21,418 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

T. Rowe Price Associates first reported a position in BIOA in Q3 2024 and has held it in 4 quarters since. The position peaked at $9.36M in Q3 2024. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • T. Rowe Price Associates held 21,418 shares of BioAge Labs worth $375K as of Q1 2026.
  • T. Rowe Price Associates bought 6,610 BioAge Labs shares in Q1 2026, an estimated $127K.
  • BioAge Labs made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2568 holding.
  • T. Rowe Price Associates first reported a position in BioAge Labs in Q3 2024 and has held it in 4 quarters since.
  • T. Rowe Price Associates's BioAge Labs position peaked at $9.36M in Q3 2024.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.